安罗替尼对卡瑞利珠单抗在治疗进展期非小细胞肺癌中引起反应性毛细血管增生症的缓解作用分析  

Anlotinib Salvages the Reactive Capillary Hemangiomas Induced by Camrelizumab in NSCLC

作　　者：尹楠楠 李庆妍 王保庆 于博 YIN Nannan;LI Qingyan;WANG Baoqing;YU Bo(Department of Clinical Pharmacy,the Second Affiliated Hospital of Xuzhou Medical University,Xuzhou 221006,China;Department of Medical Oncology,the Second Affiliated Hospital of Xuzhou Medical University,Xuzhou 221006,China)

机构地区：[1]徐州医科大学第二附属医院药学部,徐州221006 [2]徐州医科大学第二附属医院肿瘤内科,徐州221006

出　　处：《药学与临床研究》2023年第6期547-550,共4页Pharmaceutical and Clinical Research

基　　金：江苏省药学会—天晴医院药学基金(Q202051)。

摘　　要：目的:探讨安罗替尼对卡瑞利珠单抗在治疗进展期非小细胞肺癌(NSCLC)中引起反应性毛细血管增生症(RCHs)的缓解作用。方法:纳入136例使用卡瑞利珠单抗治疗的进展期NSCLC患者,随机分为卡瑞利珠单抗+安罗替尼组(观察组,73例)和卡瑞利珠单抗+安慰剂组(对照组,63例)。两组均随访25周,每用药2个周期(42天)评价一次疗效和安全性,主要指标包括发病时间、持续时间和严重程度。结果:79例(58.09%)患者出现RCHs,其中观察组31例(42.47%),对照组48例(76.19%),观察组RCHs发生率显著低于对照组,差异有统计学意义(P<0.001)。观察组RCHs的出现时间迟于对照组,消退时间则短于对照组,差异有统计学意义(P<0.001)。两组RCHs严重程度比较,差异无统计学意义(P=0.721)。结论:RCHs是卡瑞利珠单抗治疗的进展期NSCLC患者中常见的皮肤毒性反应,联合安罗替尼可降低卡瑞利珠单抗相关RCHs的发生率并诱导其快速消退。Objective:To explore the alleviating effects of anlotinib on reactive capillary hemangiomas(RCHs)induced by carolizumab in the treatment of advanced NSCLC.Methods:A total of 136 patients with advanced NSCLC who were treated with carolizumab were randomly divided into carolizumab+anlotinib group(observation group,73 cases)and carolizumab+placebo group(control group,63 cases).Both groups were followed up for 25 weeks,with efficacy and safety evaluated every 2 cycles(42 days)of medication.The main indicators included onset time,duration and severity of RCHs.Results:A total of 79 patients(58.09%)developed RCHs.Among them,there were 31 cases(42.47%)in the observation group,and 48 cases(76.19%)in the control group.The incidence of RCHs in the observation group was significantly lower than that in the control group,and the difference was statistically significant(P<0.001).The onset time and duration of RCHs in the observation group were later and shorter than those in the control group,and the differences were statistically significant(P<0.001).There was no statistical significance in the severity of RCHs between the two groups(P=0.721).Conclusion:RCHs are common skin toxic reactions in patients with advanced NSCLC treated with carlizumab,and the combination of anlotinib can reduce the incidence of carlizumab associated RCHs and induce their rapid regression.

关 键 词：安罗替尼 卡瑞利珠单抗 非小细胞肺癌 反应性毛细血管增生症 

分 类 号：R969.3[医药卫生—药理学] R734[医药卫生—药学]